Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

BELLUS Health logo

About BELLUS Health Stock (NASDAQ:BLU)

Advanced Chart

Key Stats

Today's Range
$14.74
$14.75
50-Day Range
$14.42
$14.75
52-Week Range
$6.38
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

BLU Stock Analysis - Frequently Asked Questions

BELLUS Health Inc. (NASDAQ:BLU) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include NIO (NIO), Meta Platforms (META), Pfizer (PFE), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

Last Earnings
11/10/2021
Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
Employees
74
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.08 million
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$15 thousand
Price / Sales
124,613.93
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
4.77

Miscellaneous

Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:BLU) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners